A Phase 2 Study of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Diet and Exercise - Trial NCT06411275
Access comprehensive clinical trial information for NCT06411275 through Pure Global AI's free database. This Phase 2 trial is sponsored by HighTide Biopharma Pty Ltd and is currently Completed. The study focuses on Type 2 Diabetes Mellitus. Target enrollment is 113 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
HighTide Biopharma Pty Ltd
Timeline & Enrollment
Phase 2
Mar 31, 2022
Jan 17, 2023
Primary Outcome
Mean change in HbA1c
Summary
The goal of this clinical trial is to evaluate the efficacy and safety of berberine
 ursodeoxycholate (HTD1801) compared to placebo in patients with type 2 diabetes inadequately
 controlled with diet and exercise alone.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06411275
Non-Device Trial